Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Obesity and Allometric Scaling of Pharmacokinetics

This is a preview of subscription content, log in to check access.


  1. 1.

    Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71–87

  2. 2.

    Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303–32

  3. 3.

    Peeters MYM, Allegaert K, Blussé van Oud-Alblas HJ, et al. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet 2010; 49: 269–75

  4. 4.

    Kleiber M. Body size and metabolism. Hilgardia 1932; 6: 315–51

  5. 5.

    van Kralingen S, Diepstraten J, Peeters MYM, et al. Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clinical Pharmacokinetics 2011; 50: 739–50

  6. 6.

    Cortínez LI, Anderson BJ, Penna A, et al. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br J Anaesth 2010; 105: 448–56

  7. 7.

    Servin F, Farinotti R, Haberer JP, et al. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide: a clinical and pharmacokinetic study. Anesthesiology 1993; 78: 657–65

  8. 8.

    Albertin A, Poli D, La Colla L, et al. Predictive performance of ’servin’s formula’ during BIS-guided propofol-remifentanil target-controlled infusion in morbidly obese patients. Br J Anaesth 2007; 98: 66–75

  9. 9.

    Ingrande J, Brodsky JB, Lemmens HJ. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth Analg 2011; 113: 57–62

  10. 10.

    van Kralingen S, Diepstraten J, van de Garde EMW, et al. Comparative evaluation of propofol 350 and 200 mg for induction of anaesthesia in morbidly obese patients: a randomized double-blind pilot study. Eur J Anaesthesiol 2010; 27: 572–4

  11. 11.

    La Colla L, Albertin A, La Colla G, et al. No adjustment vs adjustment formula as input weight for propofol target-controlled infusion in morbidly obese patients. Eur J Anaesthesiol 2009; 26: 362–9

  12. 12.

    La Colla L, Albertin A, La Colla G. Pharmacokinetic model-driven remifentanil administration in the morbidly obese: the ‘critical weight’ and the ‘fictitious height’, a possible solution to an unsolved problem? Clin Pharmacokinet 2009; 48: 397–8

  13. 13.

    Coetzee JF. Total intravenous anaesthesia to obese patients: largely guesswork? Eur J Anaesthesiol 2009; 26: 359–61

  14. 14.

    Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth 2010; 105 Suppl. 1: i16–23

  15. 15.

    Lemmens HJM. Perioperative pharmacology in morbid obesity. Curr Opin Anaesthesiol 2010; 23: 485–91

Download references


No sources of funding were used to assist in the preparation of this commentary. The authors have no conflicts of interest that are directly relevant to the content of this commentary.

Author information

Correspondence to Dr Johannes H. Proost.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Eleveld, D.J., Proost, J.H., Absalom, A.R. et al. Obesity and Allometric Scaling of Pharmacokinetics. Clin Pharmacokinet 50, 751–753 (2011). https://doi.org/10.2165/11594080-000000000-00000

Download citation


  • Body Composition
  • Obese Individual
  • Drug Clearance
  • Allometric Scaling
  • Allometric Exponent